Evaluation of the clinical effect of pharmacist intervention

Q4 Pharmacology, Toxicology and Pharmaceutics European Journal of Oncology Pharmacy Pub Date : 2020-01-01 DOI:10.1097/OP9.0000000000000023
D. K. Farrag, N. Sabri, Amr Shafik Tawfik, S. Shaheen
{"title":"Evaluation of the clinical effect of pharmacist intervention","authors":"D. K. Farrag, N. Sabri, Amr Shafik Tawfik, S. Shaheen","doi":"10.1097/OP9.0000000000000023","DOIUrl":null,"url":null,"abstract":"Introduction:Breast cancer is one of the most common cancers among Egyptian women. Health-related quality of life (QOL) and reduction of side-effects play an important role for the treatment of cancer patients. The purpose of this prospective study was to determine if pharmacist’s intervention could improve clinical outcomes of patient with breast cancer. Patients and methods: This study was a single-center interventional prospective study carried out on a group of 60 breast cancer patients at Clinical Oncology Department, Ain Shams University Hospitals from June 2017 to May 2018 patients were subjected to a thorough history taking, assessment of treatment-related adverse events before each cycle and at the end of the treatment. In addition, assessment of QOL was done at the baseline and at the end of treatment to evaluate the effect of the pharmacist’s interventions. Results:The present study has shown that the clinical pharmacist interventions were associatedwith significant decrease of toxicity grades of patients, for example, anemia where the percentage of patients of grade 2 decreased from 17% to 1.7%; moreover, 5% of patients had grade 4 nausea/vomiting, while after pharmacist intervention, it became 0%. Regarding patients’ QOL, results of the present study showed improvement of mean±standard deviation of most of the QOL scales such as systematic therapy side-effects decreased from 80.8±19.53 to 42.8±16.8, all with P<0.001. Conclusions:Most treatments for breast cancer despite beneficial result in toxicities, primarily anemia, neutropenia, nausea, and pain. These side-effects adversely impact patient QOL and can lead to treatment discontinuation. Clinical pharmacist intervention resulted in beneficial clinical outcomes in patients with breast cancer such as the reduction of treatment-related side-effects and the improvement of patients’ QOL. Abbreviations: QOL = quality of life; SD = standard deviation; SPSS = Statistical Package for Social Sciences.","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000023","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Oncology Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/OP9.0000000000000023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 2

Abstract

Introduction:Breast cancer is one of the most common cancers among Egyptian women. Health-related quality of life (QOL) and reduction of side-effects play an important role for the treatment of cancer patients. The purpose of this prospective study was to determine if pharmacist’s intervention could improve clinical outcomes of patient with breast cancer. Patients and methods: This study was a single-center interventional prospective study carried out on a group of 60 breast cancer patients at Clinical Oncology Department, Ain Shams University Hospitals from June 2017 to May 2018 patients were subjected to a thorough history taking, assessment of treatment-related adverse events before each cycle and at the end of the treatment. In addition, assessment of QOL was done at the baseline and at the end of treatment to evaluate the effect of the pharmacist’s interventions. Results:The present study has shown that the clinical pharmacist interventions were associatedwith significant decrease of toxicity grades of patients, for example, anemia where the percentage of patients of grade 2 decreased from 17% to 1.7%; moreover, 5% of patients had grade 4 nausea/vomiting, while after pharmacist intervention, it became 0%. Regarding patients’ QOL, results of the present study showed improvement of mean±standard deviation of most of the QOL scales such as systematic therapy side-effects decreased from 80.8±19.53 to 42.8±16.8, all with P<0.001. Conclusions:Most treatments for breast cancer despite beneficial result in toxicities, primarily anemia, neutropenia, nausea, and pain. These side-effects adversely impact patient QOL and can lead to treatment discontinuation. Clinical pharmacist intervention resulted in beneficial clinical outcomes in patients with breast cancer such as the reduction of treatment-related side-effects and the improvement of patients’ QOL. Abbreviations: QOL = quality of life; SD = standard deviation; SPSS = Statistical Package for Social Sciences.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
药师干预的临床效果评价
乳腺癌是埃及妇女中最常见的癌症之一。健康相关生活质量(QOL)和减少副作用对癌症患者的治疗起着重要作用。本前瞻性研究的目的是确定药师干预是否可以改善乳腺癌患者的临床结果。患者和方法:本研究是一项单中心介入前瞻性研究,对2017年6月至2018年5月在艾因沙姆斯大学附属医院临床肿瘤科的60名乳腺癌患者进行了研究,患者在每个周期前和治疗结束时进行了全面的病史记录,评估了治疗相关的不良事件。此外,在治疗开始时和治疗结束时进行生活质量评估,以评估药师干预措施的效果。结果:本研究表明,临床药师干预与患者毒性等级的显著降低有关,例如贫血,2级患者的百分比从17%下降到1.7%;此外,5%的患者有4级恶心/呕吐,而经过药师干预后,这一比例变为0%。对于患者的生活质量,本研究结果显示,系统治疗副作用等大部分生活质量量表的平均值±标准差从80.8±19.53降至42.8±16.8,均P<0.001。结论:大多数乳腺癌治疗方法尽管有益,但仍有毒性,主要是贫血、中性粒细胞减少、恶心和疼痛。这些副作用会对患者的生活质量产生不利影响,并可能导致治疗中断。临床药师的干预使乳腺癌患者获得了治疗相关副作用减少、患者生活质量提高等良好的临床结果。缩写:QOL =生活质量;SD =标准差;SPSS =社会科学统计软件包。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.40
自引率
0.00%
发文量
4
期刊最新文献
Genotypic variations of the CYP2D6 gene in patients with breast cancer treated with tamoxifen: case series Alternative chemotherapy for acute myeloid leukemia with Down syndrome Physicochemical stability of pemetrexed diarginine at 25 mg/mL in partially-used vials and at 3 and 12 mg/mL diluted in dextrose 5% or in sodium chloride 0.9% in polyolefin bags Cost-effectiveness analysis of pembrolizumab versus standard of care in recurrent or metastatic squamous cell carcinoma of the head and neck Impact of COVID-19 of oncology pharmacy services: Results of 8-months survey
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1